Surrozen (SRZN) Accumulated Depreciation (2020 - 2025)
Surrozen (SRZN) posted quarterly Accumulated Depreciation of $8.4 million for Q4 2025, up 6.73% year-over-year from $7.8 million in Q4 2024, and up 6.73% quarter-over-quarter from $7.8 million in Q4 2024.
Surrozen (SRZN) Accumulated Depreciation (2020 - 2025) Analysis & Trends
Surrozen's Accumulated Depreciation history runs 6 years deep, the most recent figure standing at $8.4 million for Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 6.73% year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at $8.4 million (up 6.73% YoY), while the FY2025 annual figure was $8.4 million, up 6.73% from the prior year.
- Accumulated Depreciation for Q4 2025 stood at $8.4 million, up from $7.8 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $11.4 million in Q4 2022, with the low at $7.4 million in Q4 2023.
- The 5-year median for Accumulated Depreciation is $8.4 million (2025), against an average of $8.9 million.
- The sharpest annual moves came in 2021 and 2023: Accumulated Depreciation increased 23.16% in 2021, then slumped 35.11% in 2023.
- Surrozen's Accumulated Depreciation stood at $9.5 million in 2021, then climbed by 19.01% to $11.4 million in 2022, then plunged by 35.11% to $7.4 million in 2023, then advanced by 6.5% to $7.8 million in 2024, then rose by 6.73% to $8.4 million in 2025.
- Business Quant data shows SRZN's Accumulated Depreciation at $8.4 million in Q4 2025, $7.8 million in Q4 2024, and $7.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.38 Mn |
| Dec 31, 2024 | 7.85 Mn |
| Dec 31, 2023 | 7.37 Mn |
| Dec 31, 2022 | 11.36 Mn |
| Dec 31, 2021 | 9.54 Mn |
| Dec 31, 2020 | 7.75 Mn |